| scholarly article | Q13442814 |
| P50 | author | Seyed MohammadReza Hashemian | Q51686741 |
| P2093 | author name string | Tayebeh Farhadi | |
| Zinat Farhadi | |||
| P2860 | cites work | MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli | Q24671787 |
| Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance | Q26853135 | ||
| Exploring the hidden potential of fosfomycin for the fight against severe Gram-negative infections | Q28072033 | ||
| Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats | Q28374187 | ||
| Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli | Q30451453 | ||
| Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria | Q33534711 | ||
| Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae | Q33816251 | ||
| Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26 | Q33976610 | ||
| In vitro activity of fosfomycin in combination with various antistaphylococcal substances. | Q34085557 | ||
| The mechanism of action of fosfomycin (phosphonomycin) | Q34214482 | ||
| Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily | Q34482492 | ||
| Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship | Q34591740 | ||
| Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance | Q35960788 | ||
| Fosfomycin | Q36675246 | ||
| Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections | Q37614630 | ||
| Fosfomycin: an old, new friend? | Q37633415 | ||
| Fosfomycin: an old--new antibiotic | Q37931369 | ||
| The revival of fosfomycin | Q37938425 | ||
| Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists | Q38208281 | ||
| In silico phylogenetic analysis of Vibrio cholerae isolates based on three housekeeping genes. | Q39018518 | ||
| Fosfomycin: Mechanism and Resistance | Q39071416 | ||
| Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli. | Q39473127 | ||
| Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. | Q39475307 | ||
| Virtual Screening for Potential Inhibitors of CTX-M-15 Protein of Klebsiella pneumoniae. | Q40259704 | ||
| The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents | Q40517235 | ||
| Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation | Q40612725 | ||
| Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin | Q41149840 | ||
| Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa | Q42170768 | ||
| Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock | Q43541038 | ||
| Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats | Q43781855 | ||
| Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay | Q43961938 | ||
| Tissue distribution of imipenem in critically ill patients | Q43994394 | ||
| Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis | Q44116286 | ||
| Target site penetration of fosfomycin in critically ill patients | Q44385715 | ||
| Effect of non-beta-lactam antibiotics on penicillin-binding protein synthesis of Enterococcus hirae ATCC 9790. | Q44467186 | ||
| Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. | Q44824183 | ||
| An increase in the antimicrobial activity in vitro of fosfomycin under anaerobic conditions | Q44923509 | ||
| Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue | Q44995115 | ||
| Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae. | Q46968587 | ||
| Fosfomycin: Pharmacological, Clinical and Future Perspectives. | Q47136072 | ||
| Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. | Q51017942 | ||
| In vitro activity of fosfomycin against 'problem' gram-positive cocci | Q54280088 | ||
| In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. | Q54326122 | ||
| Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. | Q54460259 | ||
| Fosfomycin monophosphate and fosfomycin diphosphate, two inactivated fosfomycin derivatives formed by gene products of fomA and fomB from a fosfomycin producing organism Streptomyces wedmorensis. | Q54589592 | ||
| Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. | Q54590227 | ||
| Characterization of spontaneous fosfomycin (phosphonomycin)-resistant cells of Escherichia coli B in vitro | Q54621230 | ||
| Computer-aided design of amino acid-based therapeutics: a review. | Q55315041 | ||
| Linezolid: a review of its properties, function, and use in critical care. | Q55368160 | ||
| Adverse events associated with intravenous fosfomycin | Q60673026 | ||
| Pharmacokinetics of Phosphonomycin in Man I:Intravenous Administration | Q70617150 | ||
| In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii | Q73046683 | ||
| In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa | Q73230024 | ||
| Surgery and intensive care procedures affect the target site distribution of piperacillin | Q73981260 | ||
| Pharmacodynamics, a tool for a better use of antibiotics? | Q73984716 | ||
| Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia | Q73984729 | ||
| Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis | Q74492356 | ||
| Fosfomycin Monophosphate and Fosfomycin Diphosphate, Two Inactivated Fosfomycin Derivatives Formed by Gene Products of fomA and fomB from a Fosfomycin Producing Organism Streptomyces wedmorensis. | Q78422728 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 525-530 | |
| P577 | publication date | 2019-03-27 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Fosfomycin: the characteristics, activity, and use in critical care | |
| P478 | volume | 15 |
Search more.